Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have been given an average rating of “Hold” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $3.90.
AKBA has been the topic of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Akebia Therapeutics in a research note on Tuesday, September 15th. Zacks Research raised Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings downgraded Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a research report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th.
Check Out Our Latest Analysis on Akebia Therapeutics
Akebia Therapeutics Stock Performance
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $49.13 million for the quarter, compared to analysts’ expectations of $48.85 million. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%. On average, equities research analysts expect that Akebia Therapeutics will post -0.14 earnings per share for the current year.
Institutional Trading of Akebia Therapeutics
Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its position in Akebia Therapeutics by 697.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,622 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 18,037 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Akebia Therapeutics in the 2nd quarter valued at approximately $26,000. Hsbc Holdings PLC purchased a new stake in Akebia Therapeutics in the 2nd quarter valued at approximately $27,000. Legal & General Group Plc acquired a new position in Akebia Therapeutics during the 2nd quarter worth approximately $30,000. Finally, Empirical Asset Management LLC acquired a new position in Akebia Therapeutics during the 2nd quarter worth approximately $40,000. Institutional investors and hedge funds own 33.92% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for patients with kidney disease and related complications. The company’s portfolio centers on therapies for anemia associated with chronic kidney disease (CKD), a condition that can result from reduced kidney function and insufficient production of erythropoietin.
Akebia’s primary product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In the United States, Vafseo is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least three months.
Featured Stories
- Five stocks we like better than Akebia Therapeutics
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
